摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-吡啶基)苯硼酸频哪醇酯 | 1009033-87-7

中文名称
4-(4-吡啶基)苯硼酸频哪醇酯
中文别名
4-[4-(4,4,5,5-四甲基-1,3,2-二氧硼烷-2-基)苯基]-吡啶;4-(4-吡啶基)苯基硼酸频哪醇酯
英文名称
4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine
英文别名
4-(4-pyridyl)phenylboronic acid pinacol ester;4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyridine
4-(4-吡啶基)苯硼酸频哪醇酯化学式
CAS
1009033-87-7
化学式
C17H20BNO2
mdl
——
分子量
281.162
InChiKey
PTNMCYWJKRZCDE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    265℃
  • 沸点:
    401℃
  • 密度:
    1.09
  • 闪点:
    197℃

计算性质

  • 辛醇/水分配系数(LogP):
    3.05
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335

SDS

SDS:4c2b3e5fe55be83eb43d5f452e81b01b
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-(Pyridin-4-yl)phenylboronic acid, pinacol ester
Synonyms: 4-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-pyridine

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Pyridin-4-yl)phenylboronic acid, pinacol ester
CAS number: 1009033-87-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H20BNO2
Molecular weight: 281.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(4-吡啶基)苯硼酸频哪醇酯四(三苯基膦)钯caesium carbonate 作用下, 以 甲醇甲苯 为溶剂, 生成 4-(2',5'-bis(2-ethylhexyl)-4''-(10-phenylanthracen-9-yl)-[1,1':4',1''-terphenyl]-4-yl)pyridine
    参考文献:
    名称:
    从隧道到跳跃介导的从量子点到分子的三重态能量转移的演变
    摘要:
    有效的能量转移对于单线态裂变和光子上转换等多激子过程尤为重要。这里报道了在三重态激子从 CdSe 纳米晶体转移到蒽期间从短程隧穿到长程跳跃的转变。这得到了稳态光子上转换测量、三重态能量转移 (TET) 效率的直接代表以及瞬态吸收测量的坚定支持。当亚苯基桥最初插入在 CdSe 纳米晶体供体和蒽受体之间时,TET 的速率呈指数下降,与光子上转换量子效率从 11.6% 下降到 4.51% 到 0.284% 相称,正如隧道机制所预期的那样。然而,随着刚性桥长度增加到 4 和 5 个亚苯基单元,光子上转换 QY 再次增加到 0.468% 和 0.413%,比使用 3 个亚苯基单元时高 1.5-1.6 倍(使用最大上转换量子效率为 100% 的惯例)。这表明从激子隧穿到跳跃的转变,导致超出传统 1 nm Dexter 距离的相对高效且与距离无关的 TET。瞬态吸收光谱用于确认从 CdSe 到发射器的三
    DOI:
    10.1021/jacs.0c07727
  • 作为产物:
    描述:
    对溴碘苯 在 bis-triphenylphosphine-palladium(II) chloride 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloridepotassium acetatepotassium carbonate 作用下, 以 1,4-二氧六环乙醇甲苯 为溶剂, 反应 32.0h, 生成 4-(4-吡啶基)苯硼酸频哪醇酯
    参考文献:
    名称:
    光诱导质子耦合电荷转移触发反离子定向易位
    摘要:
    光触发的ClO 4 -阴离子沿着BPym-OH染料从阳离子到中性结合位点的易位通过发射可视化。时间分辨荧光和分子动力学模拟的结合使其能够在时间和能量域中进行描述。该反应产生显着的红移荧光,延伸至近红外,出现在约 83 ps 处,这是由耦合质子-电子转移的电致变色调制产生的。
    DOI:
    10.1002/anie.202403317
点击查看最新优质反应信息

文献信息

  • [EN] ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, DISPLAY ELEMENT, AND DIMMING ELEMENT<br/>[FR] COMPOSÉ ÉLECTROCHROMIQUE, COMPOSITION ÉLECTROCHROMIQUE, ÉLÉMENT D'AFFICHAGE ET ÉLÉMENT DE GRADATION
    申请人:RICOH CO LTD
    公开号:WO2014208775A1
    公开(公告)日:2014-12-31
    An electrochromic compound, represented by the following general formula (I): where X1 to X4 are each a substituent represented by the following general formula (II), an alkyl group that may contain a functional group, an aromatic hydrocarbon group that may contain a functional group, or a hydrogen atom, and at least two selected from X1 to X4 are the substituents represented by the general formula (II): where R1 to R8 are each independently a hydrogen atom, or a monovalent group that may contain a substituent; B is a substituted or unsubstituted monovalent group that may contain a functional group; A- is a monovalent anion; and m is any of 0 to 3, and R1 to R8, B, and m may each independently be different when a plurality of the substituents represented by the general formula (II) are present.
    一个电致变色化合物,由以下通用式(I)表示:其中X1至X4分别是由以下通用式(II)表示的取代基,可能包含功能基团的烷基基团,可能包含功能基团的芳香烃基团,或氢原子,并且X1至X4中至少有两个是由通用式(II)表示的取代基:其中R1至R8分别独立地是氢原子,或可能包含取代基的一价基团;B是可能包含功能基团的取代或未取代的一价基团;A-是一价阴离子;m为0至3中的任意值,当存在多个由通用式(II)表示的取代基时,R1至R8、B和m可能各自独立不同。
  • [EN] OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY<br/>[FR] OXINDOLES SUBSTITUÉS PAR OLÉFINE AYANT UNE ACTIVITÉ SUR AMPK
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2014202528A1
    公开(公告)日:2014-12-24
    The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    本发明涉及具有有价值的药理特性的式(I)化合物,特别是AMPK激活剂,因此在治疗某些可以通过激活该受体预防或治疗的疾病方面具有用处。这些化合物适用于治疗和预防可以受该受体影响的疾病,如代谢性疾病,特别是2型糖尿病。
  • Cavitand‐Based Pd‐Pyridyl Coordination Capsules: Guest‐Induced Homo‐ or Heterocapsule Selection and Applications of Homocapsules to the Protection of a Photosensitive Guest and Chiral Capsule Formation
    作者:Munechika Nakamura、Yoshimi Tsukamoto、Takuro Ueta、Yoshihisa Sei、Takanori Fukushima、Kenji Yoza、Kenji Kobayashi
    DOI:10.1002/asia.202000603
    日期:2020.7.16
    ) and Pd(dppp)(OTf)2 self‐assembles into a homocapsule 1 2 ⋅ [Pd(dppp)]4}8+ ⋅ (TfO−)8 (C1 ) or 2 2 ⋅ [Pd(dppp)]4}8+ ⋅ (TfO−)8 (C2 ), respectively, through Pd−Npy coordination bonds. A 1 : 1 : 4 mixture of 1 , 2 , and Pd(dppp)(OTf)2 produced a mixture of homocapsules C1 , C2 , and a heterocapsule 1  ⋅ 2  ⋅ [Pd(dppp)]4}8+ ⋅ (TfO−)8 (C3 ) in a 1 : 1 : 0.98 mole ratio. Selective formation (self‐sorting)
    四[[4-(4-吡啶基)苯基]乙炔基(1)或四[4-(4-吡啶基)苯基乙炔基]丙二醇(2)和Pd(dppp)(OTf)2的2:4混合物自组装成一个homocapsule 1 2  ⋅[钯(DPPP)] 4 } 8+  ⋅(TFO - )8(C1)或 2 2  ⋅[钯(DPPP)] 4 } 8+  ⋅(TFO - )8(C2),分别通过Pd-Npy配位键。A 1:1:4的混合物1,2,和Pd(DPPP)(OTF)2产生homocapsules的混合物C1,C2,和一个heterocapsule 1  ⋅  2  ⋅[钯(DPPP)] 4 } 8+  ⋅(TFO - )8(C3)以1:1:0.98的摩尔比。均质胶囊C1和C2或杂质胶囊C3的选择性形成(自我分选)是在热力学控制下通过客体诱导的包封来控制的。演示了Pd-Npy配位胶囊在1中的应用。胶囊C1用作反式保护纳米容器-4,4'-
  • [EN] 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 3-(PYRAZOLYL)-1H-PYRROLO[2,3-B]PYRIDINE EN TANT QU'INHIBITEURS DE KINASE
    申请人:AURIGENE DISCOVERY TECH LTD
    公开号:WO2014006554A1
    公开(公告)日:2014-01-09
    The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.
    本申请涉及一种新型的3-(吡唑基)-lH-吡咯并[2,3-b]吡啶衍生物,其化学式为(I),作为蛋白激酶抑制剂。该发明特别涉及化合物的化学式(I)、化合物的制备以及其药物组成。该发明还涉及药用可接受的盐和组合物,包括所述新型的3-(吡唑基)-lH-吡咯并[2,3-b]吡啶衍生物及其在治疗各种疾病中的应用。
  • Hydrogenation of Borylated Arenes
    作者:Marco Wollenburg、Daniel Moock、Frank Glorius
    DOI:10.1002/anie.201810714
    日期:2019.5.13
    abundant aryl boronic acids and their derivatives catalyzed by rhodium cyclic (alkyl)(amino)carbene (Rh–CAAC) is reported. The reaction tolerates a variety of boron‐protecting groups and provides direct access to a broad scope of saturated, borylated carbo‐ and heterocycles with various functional groups. The transformation is strategically important because the versatile saturated boronate products are
    据报道,环状(烷基)(氨基)卡宾铑(Rh–CAAC)催化了丰富的芳基硼酸及其衍生物的顺式选择性氢化。该反应可耐受各种硼保护基,并可以直接进入具有各种官能团的各种饱和,硼化的碳环和杂环。该转变在战略上很重要,因为通用的饱和硼酸酯产品很难用其他方法制备。硼基的后官能化证明了饱和环状结构单元的效用。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-